Dr Reddy's launches new generic in the US

Dr Reddy's Laboratories announces the launch of Bupropion HCl Extended-Release Tablets, USP (SR) in the US Market


Dr. Reddy's Laboratories announced that it has launched Bupropion HCl extended-release tablets, USP (SR) in 100 mg, 150 mg and 200 mg, a therapeutic equivalent generic version of Wellbutrin SR (bupropion HCl) Sustained-Release Tablets in the United States market approved by the U.S. Food & Drug Administration (USFDA).

The Wellbutrin SR brand and generic had U.S. sales of approximately $109.6 million MAT for the most recent twelve months ending in July 2016 according to IMS Health.

Also read: '8% of investments in start-ups are made in the healthcare sector'

Dr. Reddy's Buproprion SR tablets are available in 100 mg, 150 mg and 200 mg, in bottle count sizes of 60, 100 and 500.

Wellbutrin SR is a registered trademark of the GSK group of companies.


Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

Union Budget

Has Union budget 2017 addressed all requirements of healthcare industry?

Send this article by email